OpGen’s (OPGN) Buy Rating Reaffirmed at HC Wainwright

OpGen (NASDAQ:OPGN – Get Rating)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday, TipRanks reports. They presently have a $3.00 price objective on the medical research company’s stock. HC Wainwright’s target price indicates a potential upside of 455.56% from the company’s previous close.

Several other research analysts also recently weighed in on the company. Zacks Investment Research raised OpGen from a “sell” rating to a “hold” rating in a research note on Thursday, May 19th. StockNews.com initiated coverage on OpGen in a research note on Wednesday. They set a “sell” rating for the company.

NASDAQ:OPGN traded up $0.06 during trading hours on Friday, reaching $0.54. The company had a trading volume of 5,297 shares, compared to its average volume of 375,059. OpGen has a 1-year low of $0.31 and a 1-year high of $3.72. The firm has a market cap of $25.14 million, a PE ratio of -0.64 and a beta of -0.50. The business’s 50 day moving average price is $0.59 and its 200-day moving average price is $0.92. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.76 and a quick ratio of 1.93.

OpGen (NASDAQ:OPGN – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The medical research company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.19). The company had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.40 million. OpGen had a negative net margin of 680.36% and a negative return on equity of 72.67%. During the same period in the previous year, the firm posted ($0.35) earnings per share. On average, analysts expect that OpGen will post -0.54 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of OPGN. GSA Capital Partners LLP purchased a new stake in OpGen in the 1st quarter valued at $73,000. Arete Wealth Advisors LLC lifted its stake in shares of OpGen by 70.0% in the 1st quarter. Arete Wealth Advisors LLC now owns 85,000 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 35,000 shares during the last quarter. BlackRock Inc. lifted its stake in shares of OpGen by 329.7% in the 4th quarter. BlackRock Inc. now owns 421,466 shares of the medical research company’s stock valued at $422,000 after purchasing an additional 323,388 shares during the last quarter. Virtu Financial LLC lifted its stake in shares of OpGen by 205.1% in the 4th quarter. Virtu Financial LLC now owns 83,227 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 55,946 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of OpGen in the 4th quarter valued at $238,000. Hedge funds and other institutional investors own 10.95% of the company’s stock.

OpGen Company Profile (Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Featured Stories